Thursday, June 24, 2021
Home Latest Pharma-News Sanofi launches its new global employee share ownership plan

Sanofi launches its new global employee share ownership plan

June 7, 2021: “Sanofi launches Action 2021, its global employee share ownership plan, open to 92,000 employees in 73 countries.

The program, similar to programs carried out since 2013, clearly demonstrates the ongoing commitment of Sanofi and its Board of Directors to involve all employees, across all its territories, in the future development and results of the company.

- Advertisement -

“The record level of employee participation in last year’s share plan demonstrated our employee’s commitment to the company and our long-term strategy and growth.

With the continued support of the Board of Directors, we want our employees to have these opportunities to be increasingly involved in Sanofi’s success by sharing in its performance,” said Paul Hudson, Chief Executive Officer of Sanofi.

As of today, the shares will be offered at a subscription price of 69,38€, which is equal to a 20% discount off the average of the 20 opening prices of Sanofi shares from May 6 to June 2, 2021.

In addition, for every five shares subscribed, employees will be able to receive one free share (up to a maximum of four free shares per employee).

And finally, each employee will be able to purchase up to 1,500 Sanofi shares within the legal limit of a maximum payment amount that does not exceed 25% of their gross annual salary, minus any voluntary deductions already made under employee savings schemes (Group Savings Plan and/or Group Retirement Savings Plan) during the year 2021.

In 2020, the employee share ownership plan, open to around 90,000 employees in 72 countries, saw its overall uptake rate exceed 36%. More than 33,000 Sanofi employees chose to invest in the company.

Today, nearly 90,000 current or former employees of the company are direct or indirect shareholders of Sanofi, and hold approximately 2.8% of its capital.”


Please enter your comment!
Please enter your name here

2 × 2 =

Most Popular

Merck Announces Phase 3 KEYNOTE-826 Trial Met Dual Primary Endpoints of OS and PFS

June 22, 2021: Merck known as MSD outside the United States and Canada announced that the pivotal Phase 3 KEYNOTE-826 trial investigating...

EU approve Koselugo for children with neurofibromatosis & plexiform neurofibromas

June 22, 2021: "AstraZenecaand MSD's Koselugo (selumetinib) has been granted conditional approval in the EU for the treatment of symptomatic, inoperable plexiform neurofibromas (PN)...

FDA Approves First Oral Blood Thinning Medication for Children

June 21, 2021: The U.S. FDA approved Pradaxa (dabigatran etexilate) oral pellets to treat children 3 months to less than 12 years...

Sanofi and Translate Bio initiate Phase 1 clinical trial of mRNA influenza vaccine

JUNE 22, 2021: "Sanofi Pasteur, the vaccines global business unit of Sanofi and Translate Bio, a clinical-stage messenger RNA (mRNA) therapeutics company, have...